Category Archives: COVID19 News

MMR Vaccine: Prevention From Worst Symptoms of COVID 19

An Effective Remedy:

As all of you know it very well that MMR stands for measles, mumps, and rubella and this MMR vaccine can be an effective remedy to treat coronavirus. Everyone knows it very well how deadly this COVID-19 impact was over the whole world and it almost shattered everything into pieces all around the world. You would be astonished to know that the existing vaccines like the MMR vaccine for coronavirus will be equally effective against this deadly pandemic. Moreover, there are numbers of evidence that shows the existing vaccinations, like the MMR vaccine, COVID-19 protection, are very beneficial even though they are not specifically made for it. 

MMR Vaccine for Coronavirus

A Protective Layer:

The doctors all over the world are testing these existing vaccinations like MMR vaccine against COVID-19 and BCG (treats TB) if they can be proved effective against this COVID-19. The scientific studies have revealed that these vaccinations can reduce the symptoms related to the world-known pandemic. Besides, MMR shot for COVID can induce MDSCs in the patient’s body that can reduce the lung infection as well as inflammation massively and can hold up other forms of severe diseases away as well. 

Besides, if a person is MMR vaccine COVID-19 vaccinated and is found positive with COVID-19 then he/she will only show mild symptoms of COVID-19 because they are very well-protected with MMR vaccine against COVID-19 and this could be your best MMR shot ever for COVID treatment. Moreover, with MMR vaccine COVID-19 protection, you are less prone to the deadly pandemic as compared to people who do not have MMR vaccination protection with them. 

Keep Children & Old One's Safe/Secure:

The little children can also benefit from the help of this MMR vaccine for coronavirus as their body is already having a protective layer to fight against this COVID-19. Though age is a factor as well in fighting with this deadly pandemic, so if you are protected with MMR vaccine COVID-19, you are surely going to win this fight. The MMR vaccine for coronavirus provides antibodies against measles, mumps, rubella, and COVID-19. It can provide you tremendous benefits in fighting this pandemic to stay out of your body and keep the MDSCs level in your body intact and thus this MMR vaccine COVID-19 vaccination provides durability for a longer period and keep the COVID symptoms away from you. So, you are completely safe and secure with MMR short for COVID.

Moreover, the recovery rate from the COVID-19 is more because of the MMR vaccine COVID-19, that is probably the main reason that the children are also more secured with this because they are already having a protection layer in the form of MMR vaccine COVID-19 protection. So, the severity of the coronavirus can be controlled massively if we keep our children as well as old ones vaccinated with MMR vaccine COVID-19 protection. 

Less Death Rate:

Besides, if you observe minutely you will find that people who are having an MMR vaccine used massively in their day to day life, the death toll will be way less as compared to the area with more deaths because of coronavirus. Besides, an MMR vaccine COVID-19 is a protection layer you can go out with your near and dear ones safe and secure as long as you are having an MMR shot for COVID at your side.

India’s 2nd COVID-19 Vaccine for Clinical Trials

The Covid-19 has brought the whole world to a standstill. Now, every country across the globe including India are putting their whole heart in to find a suitable vaccine to handle this pandemic grippingly in a solid way. As the whole world is trying, India is also doing his bit as many pharmaceutical companies are putting their valiant part in finding the proper vaccination. One such pharmaceutical giant is, Zydus Cadila who with the approval from the DCGI (Drug Controller General Of India) have manufactured a vaccination by the name, ZyCoV-D and is ready for a 2nd vaccine trial in India.

Coronavirus Vaccine Update India

They with this approval from the DCGI for India’s 2nd COVID Vaccine trial to be conducted on people to find the perfect antidote to handle this deadly COVID chain. ZyCoV-D, is 2nd vaccine trials India is doing and it is seeming that it could be a successful affair this time. This is India’s second vaccine that came in the form of ZyCoV-D, developed by Zydus, in Ahmedabad, at its Vaccine technology center. Through the animal studies, it is revealed that this vaccine creates strong immune phenomena in the animal bodies. It can be called an Indian COVID latest vaccine update.

Now soon, Zydus is about to start their human trial and it could be conducted at the different sites in the country on several volunteers in the first two phases. Zydus Cadila chairman committee is confirming that within three months the trials can be completed and with the emergence of ZyCoV-D, the coronavirus vaccine update India will be strengthened. They also confirmed that after these two phases, if required, with DCGI’s approval, the company can go for the third phase as well and the people of India can know about the Indian COVID vaccine update more specifically. Moreover, they also emphasized only then the vaccine can be available in the market otherwise it can take time more time. So, coronavirus 2nd vaccine trials India is on the verge of getting into the market professionally and hopefully with positive results related to India 2nd COVID vaccine trial.

Zydus Cadila’s Chairman, Mr. Pankaj Patel, is very confident by the results this vaccine showed on the animals like mice, rats, and rabbits. So, he is quite optimistic about the coronavirus vaccine update in India. Moreover, this vaccine also enhanced tremendous immune response in the animal bodies and the vaccine showed a great efficacy in neutralizing the wild type viruses present in the animal bodies. So, this way, he is confident that it will be a successful campaign when it will be tried upon the human volunteers and thus it can make India’s 2nd COVID vaccine trial a great success story for the world to know.

Moreover, Zydus Cadila, Chairman, Mr. Pankaj Patel is also insisting that the Vaccine Technology Center, Ahmedabad, India provides massive accessibility with the minimum amount of bio-safety requirements. Besides, Zydus also revealed that the gene of interest making it very safe for human beings.

So, the Indian COVID vaccine update has confirmed ZyCoV-D, an effective antidote in treating the COVID pandemic with certain contradictions still hovering around. Moreover, on top of everything, 2nd vaccine trials India can be carried to the remotest of remotest location quite easily because of its improved stability and lower cold chain characteristics. If this vaccination yields positive results, the Vaccine Technology platform can be used for the modification of the vaccine and if it shows clear protection.

The Chairman committee further added that they are not going to export anytime soon and all they want to do to make India 2nd COVID vaccine trial a great success. They confirmed firstly that the demands within the country will be justified first, only then can think of something else. Moreover, they put more emphasis on Indian COVID vaccine update and on giving technology to other countries, so that they could also manufacture the vaccine accordingly.

So, India’s 2nd COVID vaccine trial can prove to be a great success story for the whole of the world and thus coronavirus vaccine update India can be made intact. One can easily analyze Indian COVID vaccine update through this that they are also manufacturing another vaccine, named Covaxin for treating COVID-19. Bharat Biotech, the manufacturer, has received approval from the DCGI to give it a go and soon will carry trials on humans in two phases. It is made relevant through ICMR, Indian Council for Medical Research, and soon it will be a great reality.

First Plasma Bank in India For COVID 19 Patients

Endless Efforts:

All over the world, it is estimated that numbers of attempts have been made and still are making as well to find the solution to heal this SARS-CoV-2. The doctors, scientists, are also coming with conclusions but so far nothing fruitful could be gained in properly treating this deadly COVID-19. So, like other countries, India is also putting endless efforts in treating this deadly pandemic and it came in the form of first plasma bank in India.

COVID-19 First Plasma Bank

What Is Blood Plasma?

Moreover, blood plasma is one of the oldest therapy in which the doctors use blood plasma of people who have recovered from this life-threatening disease. So, to control this disease the first plasma bank for corona has been opened in New Delhi, India. People rarely know what is called plasma, so for their information, it is a portion of blood without RBC, WBC, and platelet count. So, COVID-19 first plasma bank is available here in New Delhi, India to sort out the concerns of coronavirus patients. Moreover, it can also be called a plasma donation for COVID-19 in India, as it has improved accessibility related to blood plasma in treating the deadly novel coronavirus patients. So, far blood plasma proved a successful effort against this, and COVID-19 first plasma bank is the availability center for blood plasma.

It is good that the first plasma Bank in India has been established and making everything easy for the people to acquire blood plasma as early as possible here but at the same time, it is also the duty of the people who have recovered from this deadly blow, should come forward to donate their blood in the first plasma bank for corona. So, that needs of the patients and their near and dear ones could be fulfilled easily.

How It Is Effective:

Now, how blood plasma is effective in curing the COVID-19 is also a big question in people’s minds. So, for them, people who have recovered from this deadly coronavirus usually develop the antibodies in their blood called convalescent plasma and this plasma then can be inserted into the bodies of the corona patients to boost up their immune system and this therapy is called convalescent plasma therapy. So regarding this, the whole credit should go to CM of New Delhi, Mr. Arvind Kejriwal, who has made this all possible and let New Delhi became the first state in India to come up with COVID-19 first plasma bank.

According to COVID-19 first plasma bank officials, it does not take more than an hour for a plasma donor to donate blood plasma at the plasma bank. After the basic tests of the donor and all the proceedings, the donor is given an appreciation certificate for his valiant effort.

Conditions, The Donors Should Follow:

However, it is not as if anyone can come and donate plasma straightway, the plasma donation for COVID-19 in India has their terms and conditions if you want to donate your blood plasma and conditions should be fulfilled otherwise you are not liable to do that. 

Besides, there are some conditions as well that donors should keep in mind while coming for donations. So, he/she must be at least 14-day old by recovering from the disease. Moreover, the donor should weigh more than 50 kg and the age should be in from 18-60 group maximum. So, if the donors fulfill all these conditions, only then they can donate their plasma at the first plasma bank in India.

Following Initiative:

Seeing plasma donation for COVID-19 in India positive moves, other states are also going for this blood plasma initiative. So, COVID-19 first plasma bank has made a great leap forward in eliminating the deadly novel corona clouds with their first plasma bank for corona and it is yielding fruitful results as well.

Erythropoietin: Using EPO For COVID 19 Patients

All over the world, the doctors are trying their best in treating the COVID-19 with the existing medications and vaccinations. They are using many medications and one of such type is EPO for COVID-19. It is giving fruitful results so far in treating coronavirus. EPO stands for Erythropoietin and it is mainly used for anaemia but this medicine is proving beneficial in treating the coronavirus patients as well. The doping agent in it is effective against COVID-19.


Latest Analysis:

The latest studies reveal that EPO mitigates several diseases not only anaemia. This medicine has proved beneficial in treating the brain or neurological diseases, so it can minimize the effect of novel coronavirus when it attacks the brain. So, EPO to treat COVID-19 is the best option to go with. All in all, erythropoietin for COVID-19 patients is proving a boon and the experts are doing their researches to know how EPO is treating COVID-19 patients effectively and successfully too.

Yielded Fruitful Results:

The EPO coronavirus treatment has shown progressive development when it is used on COVID-19 patients and the results were spectacular as patients recovered way faster from the deadly pandemic. Erythropoietin for COVID-19 patients improves blood values and the patient significant signs of improvement within seven days. Moreover, erythropoietin drug coronavirus is equally effective in the higher altitude regions because people here use more EPOs, so they have more RBCs and that is why they are more adaptable to deficiency of oxygen as compared to the people living in the low-lying areas.

Moreover, the EPO coronavirus treatment has shown tremendous improvement in the recovery of the patients as well as in their immune systems. If you observe, you will find that the kidney or dialysis patient have not got any signs of coronavirus because in the dialysis treatment they receive erythropoietin on almost daily basis. This is the main reason that they are not even affected with even mild illnesses. EPO to treat COVID-19 is a stimulant that many athletes use it and affects your blood cells and many other tissues positively. Moreover, this erythropoietin for COVID-19 patients covers the oxygen deficiency massively and progresses it forward to the brain and muscles effectively and that is why this EPO for COVID-19 is delivering positive results and showing signs of impressive improvement from the day the medical scheduling starts with EPO coronavirus treatment.

An Erythropoietin Drug Coronavirus Plus Points:

All over the world renowned doctors have studied a lot about the erythropoietin drug coronavirus a lot and came to the conclusion that it is giving positive results in enhancing the overall health of coronavirus patients. When it is experimented on animals, it showed positive results and it was acting on the brain stem and spinal cord that control breathing process in our system simultaneously with great effect. So, it is taking care of the breathing system in an affirmative way as COVID-19 straightway starts damaging your lungs and you find difficulty in breathing. So, you can see how effective this erythropoietin drug coronavirus is! Thus, this it offers excellent immunity in the COVID-19 patients. Moreover, this erythropoietin drug coronavirus control the normal things like headaches, dizziness, and anything related to seizures also.

So, at last, though the doctors all over the world are trying this EPO coronavirus treatment on patients, but still they are waiting to get convinced with authority though it is showing vital signs in improving the health of coronavirus patients. So, they are assuming and trying this EPO to treat COVID-19 patients but still a solid authority is yet to reveal that it is effective in the reals sense.

CureVac Started Work For Developing a COVID-19 Vaccine

Beginning from the first case in China (December 2019), SARS-CoV-2 is severely affecting many countries around the world. In response to the global pandemic, researchers worldwide are using different approaches to develop a coronavirus vaccine at the earliest.

CureVac COVID19 Vaccine

To protect COVID affected patients, CureVac AG is working on the development of mRNA-based drugs for vaccines and therapeutics.

CureVac is a reputed biopharmaceutical company with headquarters in Tubingen, Germany. Founded in 2000, CureVac is the first pharma company in the world that has successfully harnessed mRNA for medical purposes. The company is proud to be part of the international helping hands towards protecting masses from the novel coronavirus. The recent success of the company relates to the Rabies program that aims to fully protect humans with two doses of only one microgram (I millionth of a gram).

The company aims to provide a cost-effective and prophylactic vaccine using unique technology. At present, their team is working on mRNA technology to bring a rapid response to prevent spreading the virus. Since 2007, the company is engaged in the prophylactic vaccine and can produce mRNA vaccines on a colossal scale.

After the Paul Ehrlich Institute, CureVac is the second German company which has begun the trial phase for the vaccine against COVID-19.

To bring practical results and to speed up the development, production, and clinical process, CureVac is in contact with various health organizations such as CEPI (Coalition for Epidemic Preparedness Innovations) and BMGF (Bill and Melinda Gates Foundation.

About mRNA Technology

A natural messenger substance, the vaccine will be a trial to activate the human body against its defence mechanism. With the mRNA technology, it is expected that the human body will recognize the protein of the coronavirus and in response will activate its immune cells to produce antibodies and T-cells against it.

Mariola Fotin-Mleczek (Chief Technology Officer of CureVac) said, “With our unique RNA technology, we prepare the human body how to fight against the virus. Our expertise and disease understanding makes us able to come up with a solution for outbreak solutions like COVID-19.

As per the recent information on the Curevac COVID trial, the company has started human trials after the idea approved by regulators. The first trial by the German biotech firm will involve 168 volunteers, of whom 144 will be given the experimental vaccine.

Many countries are contributing to bringing the coronavirus vaccine. However, projections for how long it will take to develop a vaccine vary widely. Based on the experience and knowledge, researchers need at least a year to come up with an effective solution.

Once researchers successfully create a potential vaccine then brings into the notice of the Food and Drug Administration (FDA) to check its effectiveness.

The next phase is to complete Phase I, Phase II, and Phase III clinical trials to analyze the safety and effectiveness of the drug thoroughly.

The company is expected to begin the next clinical study with several thousand participants in autumn 2020. Even if CureVac remains successful in achieving favourable results, it depends on the regulatory authorities about the availability of the vaccine on the market.

Oxford COVID-19 Vaccine’s Human Clinical Trials Started in Brazil

The latest news on COVID brings that recently Brazil has signed an agreement to experimental product vaccine against COVID-19. A deal with Oxford University and a reputed pharmaceutical company, AstraZeneca has been hired to develop a vaccine that is undergoing clinical tests.

Oxford COVID 19 Vaccine Status

With the ongoing search for COVID-19, Oxford University is leading the world to bring an effective vaccine against the virus.

As per Kate Bingham (Chair of the UK Vaccine group), it is highly expected to bring a vaccine this year, from any of the candidates. The first developed Oxford COVID 19 vaccines will probably help to relieve the symptoms instead of giving full protection to the disease.

With the 283, 757 confirmed COVID cases in the UK; the country has the hope to find something protective against the virus before winter ends.  We are putting the best efforts to improve on those timelines but not sure how much sooner will be vaccine be ready to implement, said by Sarah Gilbert (Science and technology committee, Oxford University).

With the number of COVID cases increasing in Brazil and South Africa, the vaccine trial will be soon held there. AstraZeneca, the British Pharma company, has partnered with Oxford University to develop a vaccine with two billion doses in September. Meanwhile, the US is ready with two million vaccine doses to check out for effectiveness.

To maximize the production capacity of the vaccine, AstraZeneca has signed an agreement with the Serum Institute of India and CEPI (Coalition for Epidemic Preparedness Innovations). The partnership with the world’s largest vaccine manufacturers has a significant role in helping the low-and middle-income countries.

Oxford University started initial vaccine trials in April with hundreds of volunteers which is now have expanded to 10,000 contributors. Brazil is the first country outside Britain where Oxford COVID 19 Vaccines trails were started in June.

The company is proud to collaborate with the Oxford University to speed up the development and globalization of this potential new vaccine against COVID-19, said by Mene Pangalos, Executive Vice President, AstraZeneca.

In a press conference, it has been announced by the Brazilian health ministry that the country is going to invest $127 million to get material for producing 302 million doses till December. Considering the whole deal is for 100 million vaccines that will be provided by a local vaccine maker Fiocruz.

As per Soumya Swaminathan (WHO Chief Scientist), the experimental vaccine by AstraZeneca is expected to develop the world’s leading and most advanced candidate against COVID-19.

The study focuses on evaluating the way to protect people of all ages from COVID-19 with the new vaccine called ChAd0X1 nCoV-19. Also, it will provide crucial information on the safety aspects of the vaccine by expecting an excellent immune response against the virus.

Spike glycoprotein has an essential role in the infection pathway of the SARS-CoV-2 virus, which makes use of this protein to blind to ACE2 receptors on human cells. The motive of vaccinating with ChAdOx1 nCoV-19 is to make the human body develop an immune system to the spike protein that restricts the virus to human cells, thereby prevent infection.

Is Convalescent Plasma Therapy a Safe COVID 19 treatment for patients?

Scholars and researchers in the field of health and allied sciences are working on bringing treatment to help in mitigating the spread of the COVID-19. Since the outbreak of the global pandemic, the focus is on clinical evaluation, treatment, and diagnosis of the COVID-19. But so far, no drug has been proved to be safe and effective for treating COVID-19.

As per U.S Food and Drug Administration (FDA), no drug has been approved specifically to treat people with COVID-19.

Among the few emergency use treatment options, Convalescent Plasma Therapy for COVID-19 is the one that has been used by the doctors to treat individual hospitalized patients affected with COVID global pandemic.

Blood Plasma Therapy For Coronavirus

What is Convalescent Plasma Therapy?

Convalescent plasma therapy is an old way of treating infectious diseases by supplying antibodies to patients. During this therapy, plasma is infused into patients to provide a source of antibodies against SARS-CoV-2.

Plasma is a colourless liquid component of blood that contains proteins, hormones, sugar, potassium, vitamins, sodium, calcium, clotting factors.

The blood plasma therapy COVID is not new in the field of medical science. The plasma of the patients who have been recovered from COVID contains antibodies called convalescent plasma. It is infused in patients with severe COVID-19 to fight the virus. In comparison to vaccine convalescent plasma therapy works differently. On receiving the vaccine, the immune system creates its antibodies to the microbe you are being protected. 

How did the idea of implementing this therapy come? Who took the initiative to use CPT or passive antibody therapy?

Well, physiologist Emil von Behring and bacteriologist Kitasato Shibasaburou emphasized using antibodies present in serum to treat the bacterial infection diphtheria. It was in the late 19th century when doctors used passive antibody therapy to fight against diseases like pneumonia, meningitis, and measles.

 The plasma therapy has been successful in various viral illnesses such as Ebola, diphtheria, the 2009 influenza A, and 2003 SARS-CoV. 

How effective is convalescent plasma therapy for COVID-19?

As per the study, CPT is not a win-win treatment for COVID-19 as there are ongoing studies to check the effectiveness of this treatment.

 The limited clinical information reveals that CPT may prove to be an effective treatment option for COVID-19 patients, but further studies are required to confirm its efficacy.

 Regarding the side effects associated with convalescent plasma therapy, plasma transfusions are considered safe, but some there are some side effects reported by the doctors. Fever, allergy, bronchospasm, acute lung injury, and in rare cases, the transmission of infectious diseases is probably to happen with CPT. Despite these effects, transfusion of plasma can help patients with chronic medical conditions like diabetes, heart diseases, and also to those with a weakened immune system.

 People who have been recovered from COVID-19 are eligible for blood donations with specific conditions to save the life of ill patients.

French Drugmaker Sanofi Expects to Win Approval for COVID 19 Vaccine.

The French drugmaker Sanofi Pasteur has declared to accelerate a vaccine development timeline that may receive approval from regulatory authorities in the first half of 2021.

Gsk Sanofi Coronavirus Vaccine

The company and the partner GlazoSmith Kline (GSK) announced the availability of the vaccine at the earliest, most probably in the latter half of next year.

Developing shots for COVID-19 and the flu in a deal is expected to be valued at as much as $ 2.3 billion. Concerning the Sanofi Corona virus vaccine trial, Sanofi has announced his plan to invest 610 million Euros for expanding vaccine business with two new products and research centers in its home market.

As per the agreement, Sanofi will get worldwide rights for developing infectious disease vaccines. Sanofi confirmed to have multiple COVID-19 vaccine candidates and expected to begin the clinical trials with humans in the fourth quarter of this year.

A very few numbers of volunteers were involved in Phase I vaccine trials but will increase this number to secure more reliable data sooner, said Sanofi.

Finding the right vaccine to treat COVID-19 is the first stage; the major challenge lies in the production and distribution of the product globally.

The Sanofi-GSK vaccine has a laboratory-synthesized version of the coronavirus’s “spike” protein, which is essential to enter host cells. The recombinant vaccine also contains GSK’s proprietary adjuvant that can enhance the body’s immune system to a foreign onslaught.

Also, Sanofi is preparing a different set of vaccine candidates with Translate Bio, an American therapeutics company. Based on mRNA technology, which has already been used by Sanofi’s competitors, including Moderna and a partnership between BioNTech, Pfizer, and Fosun Pharma.

Thomas Triomphe (Executive vice president at vaccines unit) states, “We strongly believe that the addition of mRNA platform to the vaccine development capabilities will prevent the world from various infectious diseases.”

The mRNA vaccines are under preclinical testing and expected to be ended by 2020 with a hope to receive approval from regulatory bodies such as the U.S Food and drug administration or the European Medicines Agency by the end of 2021.

It will be a huge success if the efforts of Sanofi and its partners meet the mark.

The severity of the disease makes people around the world impatiently waiting to get the right vaccine to stop it. A vaccine against COVID 19 will make your immune system create antibodies that will prevent you from falling sick and, thus, could save the lives.

As per the World Health Organization, It is like more than 100 vaccines are in different stages of development around the world. Even if researchers remain successful in bringing the right vaccine, then also 12 to 18 months will be required to make it ready for the public. The vaccine must go through development and testing to confirm its effectiveness against the virus or bacteria and to make sure that it does not cause other problems.

Dexamethasone: First Drug to Cut COVID- 19 Deaths

With COVID-19 cases continuing to grow, researchers worldwide are putting their best efforts to develop vaccines and treatments to reduce the damage caused.

Lifesaving COVID 19 Drug

Some of the earliest treatments will probably be drugs that are already approved or used to treat other medical conditions.

In a breakthrough for COVID-19 treatment, researchers in the UK have claimed that the standard steroid drug dexamethasone can reduce the mortality rate in COVID-19 patients.

As per the recent study by the UK, Dexamethasone is the first Lifesaving Coronavirus drug that could save lives. The study reveals that one in three deaths prevented among patients on ventilators, and one in five could be the ratio for those on oxygen.

Announced on June 16, the preliminary results about deemed Dexamethasone as a lifesaving drug for COVID-19.  Researchers at the University of Oxford said that the recovery trial clarifies that treatment with Dexamethasone will help reduce the number of deaths in COVID-19 patients.

As Dr. Tedros Adhanom Ghebreyesis (WHO director-general) said, the contribution of the University of Oxford and many hospitals in the UK has brought the first treatment that can reduce the number of deaths in COVID affected patients requiring oxygen or ventilator support.

What is Dexamethasone?

Dexamethasone is a steroid not meant for people with mild symptoms but can prove lifesaving for those with severe symptoms.  The drug is already in use to treat arthritis, lupus, psoriasis, ulcerative colitis, and breathing disorders and added to treating COVID-19 moderate to severe cases.

Dexamethasone possesses anti-inflammatory and immunosuppressant properties, used to treat the diseases caused when the body’s immune system attacks the body. For Coronavirus affected patients, the infection results in inflammation, which can be fatal in some cases if the body goes into overdrive.

The drug recommended to use for adults only and not for pregnant women or breastfeeding. Avoid Dexamethasone’s if you have a fungal infection anywhere in your body.

What does the dexamethasone trial results indicate?

For the clinical trial, Oxford researchers tested about 2,000 COVID patients, and then the results were compared to more than 4,000 patients who not given the drug. The data reveals the cut down of the death rate from 40 percent to 28 percent for the patients on ventilators.  And, for the patients, need oxygen. A reduction from 25 percent to 20 percent observed.

Being affordable and globally available, Dexamethasone gives effective treatment for the COVID-19 patients on ventilators or are on oxygen, said by Martin Landray (Oxford University Professor).

Researchers feel a lot of uncertainty about the safety and effectiveness of the corticosteroids in COVID-19. The Corticosteroids used for syndromes that are strictly related to COVID-19, including SARS, MERS, influenza, and pneumonia.

COVID19 Vaccine: Phase-2 Clinical Trials in China

COVID-19 has created havoc all over the world. Everyone wants to know when this pandemic is going to end, is there a vaccine available that can help curb the spread.

Coronavirus Vaccine News China

Well, currently, no vaccines have proved to be productive work to protect people from this scary virus, but attempts by researchers are going on, and multiple candidates are under progress. About COVID-19 vaccine trials in China, there are five vaccine candidates. Preliminary clinic trial results were positive and expected to test in a Phase 3 trial in Brazil, said by China’s vaccine maker Sinovac Biotech.

As per the Institute of Medical Biology at the Chinese Academy of Medical Sciences (IMBCAMS), Chinese researchers have started the second trial of their potential corona virus vaccine. With several vaccines are in different stages of tests globally, none of the trials have passed large-scale. The phase-2 human test is one of the six vaccines that Chinese researchers are developing against the corona virus. The first phase held in May recruited around 200 individuals to participate in the test. Phase-2 COVID-19   vaccine trials in China will emphasize the immune responses while determining the shot’s dose. This year, China expected to use a plant to produce a corona virus vaccine to meet China’s future vaccine supplies. By the end of 2020, people with special needs may use experimental vaccines under urgent circumstances, by Gao Fu (Director at the Chinese Center for Disease Control and Prevention). As per China National Biotec Group and UAE state media, China and The United Arab Emirates have launched a Phase 3 Clinical trial of a COVID-19 Vaccine China.

On June 24, 2020, this trial agreement was signed between the two countries by the G42 and the Sinopharm Group, a leading research-based pharmaceutical company and affiliate of CNBG. This collaboration is not the only vaccine at the phase 3 stage, but also the University of Oxford has begun a phase 3 trials on its vaccine with 30, 000 participants in July.

Globally, the researchers are putting efforts to find a corona virus vaccine. However, it is still unsure whether a vaccine will be available to the public, but there is a hope to produce it by early 2021.

Vaccines undergo multiple phase trials to ensure effectiveness and safety. According to the US Centers for Disease Control and Prevention, clinical development takes three phases. Phase 1 includes small groups of people to get the trial vaccine. A larger group with people having similar characteristics is involved in the phase 2 trial. A phase 3 trial can be a critical moment which may use to confirm results from phase and phase 2 vaccine trials.

The report by the World Health Organization reveals that there are 16 candidate vaccines in clinical evaluation and a further 125 in preclinical evaluation.

And while scientists and researchers are in a battle to win the Coronavirus vaccine, there is still no guarantee of how and when one will find.